LBRX - Leadership updates

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced the appointment of Susan G. Kozauer, M.D. as Chief Medical Officer. Dr. Kozauer is a leader in neuropsychiatric drug development with more than two decades of development expertise spanning early-stage clinical studies through regulatory approval. She brings extensive experience across indications such as schizophrenia, mood disorders, and behavioral manifestations of neurodegenerative diseases.

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced the appointment of Joseph Miller as Chief Financial Officer. Mr. Miller is a biopharmaceutical finance executive with more than two decades of experience leading financial strategy and operations and enterprise transformation for publicly traded biotech and pharmaceutical companies. He brings a proven track record in scaling infrastructure and teams to drive organizational growth, commercializat

Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027 Announced plans for pipeline expansion of LB-102 into new neuropsychiatric indications with strong mechanistic rationale and validating clinical and real-world experience from amisulpride Cash, cash equivalents, and marketable securities of $327.8 million as of June 30, 2026, and proceeds from recent $150.0 million private placement to fund pipeline expansion, expected to fund operations beyond Q2 2029, through multiple clinical milestones NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company")

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder, and other neuropsychiatric diseases, today announced the appointment of Christopher Zergebel as Senior Vice President, Clinical Operations. Mr. Zergebel, a seasoned biotechnology executive with more than 25 years of global development operations experience, brings deep expertise in growing and leading cross-functional teams including clinical operations, data management, and project and portfolio management. "We ar

Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression  Published results from the Phase 2 NOVA-1 trial of LB-102 in schizophrenia in The Journal of the American Medical Association (JAMA) Psychiatry Expanded pipeline following $100 million private placement with plans to initiate a Phase 2 trial of LB-102 in adjunctive treatment of major depressive disorder (MDD) in early 2027 Cash, cash equivalents, and marketable securities of $365.6 million as of March 31, 2026 expected to fund operations into Q2 2029, through multiple clinical milestones NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -

NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD) and other neuropsychiatric diseases, today announced the appointment of Robert Lenz, M.D., Ph.D. to its Board of Directors. "We are delighted to welcome Rob to our Board as his depth of expertise in neuroscience R&D brings significant value to LB Pharma at a time when we are advancing LB-102 into late-stage clinical development across multiple indications," said Heather Turner, Chief Executive Officer of LB Pharmaceuticals

NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment Dr. Minako Pazdera as General Counsel. Dr. Pazdera joins LB Pharmaceuticals with more than 25 years of experience spanning corporate governance, intellectual property, strategic corporate transactions and compliance. "We are delighted to welcome Minako to LB Pharmaceuticals," said Heather Turner, Chief Executive Officer. "Dr. Pazdera has broad expertise encompassing both financial and strateg

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointments of Ellen Rose as Senior Vice President, Corporate Affairs and Lindsay Beaupre as Senior Vice President, People and Culture. "We are pleased to welcome Ellen and Lindsay to LB Pharmaceuticals," said Heather Turner, Chief Executive Officer. "Ms. Rose has extensive experience in corporate communications, investor relations, and patient advocacy within the biopharma industry. Ms. Beaupre is a sea

NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment of Kaya Pai Panandiker as Chief Commercial Officer. Ms. Pai Panandiker is a seasoned commercial and operating leader with more than 20 years of global biopharmaceutical experience, including extensive leadership in neuroscience commercialization and in launching and scaling global brands. "We are very pleased to welcome Kaya to LB Pharmaceuticals," said Heather Turner, Chief Executive Officer

NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX) today announced the appointment of James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs. Throughout his career, Dr. Rawls has led or contributed to more than a dozen successful regulatory filings and product approvals in the United States, Europe, and Japan, with specific experience in neuropsychiatric diseases. "Dr. Rawls has a remarkable depth of regulatory expertise that will be instrumental as we advance LB-102 into a Phase 3 clinical trial in schizophrenia and a Phase 2 clinical trial in bipolar depression in 2026," said Heather Turner, Chief Execu